What systemic treatment would you offer for metastatic HER2+ breast cancer that has progressed through THP and TDM-1 with predominant CNS progression and without localized treatment options?
Given the changing landscape of treatment, some patients may have already received capecitabine previously. Would this impact your treatment recommendations?
Thank you for your answer. Could you expand on how...
The main evidence is that responses in the tucatin...